Skip to main content
    T

    Traws Pharma Inc (TRAW)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.24
    -0.02 (-8.19%)

    Market Cap: $4.00M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Traws Pharma Inc (TRAW) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Traws Pharma (TRAW) has a market cap of $4.00M and an enterprise value of $1.66M. It kept -807.29% of revenue as net income over the last 12 months. Its share count is up 93.28% from a year earlier.

    Total Valuation

    Enterprise value is 58.51% below the market cap, as cash exceeds debt.

    Market Cap$4.00M
    Enterprise Value$1.66M
    Latest price (Nov 17, 2026)$0.24

    Key Dates

    The next earnings report is expected on Apr 13, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateApr 13, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 7.44% in the quarter ended Sep 30, 2026 and grew 321.03% a year over 2 years.

    Shares Outstanding17.04M
    Shares Change (YoY)+93.28%
    Shares Change (QoQ)+7.44%
    Share Count Growth (2Y CAGR)+321.03%

    Price Statistics

    The stock is down 89.00% over 52 weeks and trades 42.86% below its 50-day average.

    Beta (1Y)1.61
    52-Week Change-89.00%
    1-Month Change-34.87%
    3-Month Change-55.80%
    6-Month Change-84.99%
    5-Year Change-99.66%
    10-Year Change-100.00%
    Total Return (1Y)-89.00%
    Total Return (3Y CAGR)-75.55%
    Total Return (5Y CAGR)-68.65%
    Max Drawdown (1Y)-92.20%
    Max Drawdown (3Y)-99.13%
    Sharpe Ratio (1Y)-1.66
    Correlation with SPY (1Y)0.17
    50-Day Average$0.42
    200-Day Average$1.04
    52-Week Range$0.22 to $2.98
    RSI (14 Days)34.4
    Average Volume (20 Days)199.76K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.52x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio0.52x
    Quick Ratio0.52x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on Assets (ROA)-281.19%
    ROA (5Y Average)-58.70%
    Asset Turnover0.26x

    Scores

    TRAW has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $2.62M over the last 12 months is down 7.97% from the 12 months before.

    Revenue$2.62M
    Revenue Growth (YoY)-7.97%
    Gross Profit$2.62M
    Operating Income-$21.09M
    Pretax Income-$21.09M
    Net Income-$21.15M
    EBITDA-$20.91M
    EBIT-$21.09M
    Reported EPS (TTM)-$1.41

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$2.34M
    Total Debt$0
    Net Cash$2.34M
    Net Cash Per Share$0.14
    Working Capital-$4.67M
    Shareholder Equity-$2.13M
    Tangible Book Value-$4.53M
    Total Assets$7.52M
    Total Liabilities$9.65M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$15.32M
    FCF Per Share-$1.16
    Depreciation and Amortization$175.00K
    Share Repurchases$2.96M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -805.00%.

    Gross Margin100.00%
    Operating Margin-805.00%
    Pretax Margin-804.85%
    Net Margin-807.29%
    EBITDA Margin-798.17%
    EBIT Margin-804.85%
    Gross Margin (5Y Average)98.94%

    Growth

    Revenue grew 131.12% a year over 3 years.

    Revenue Growth (3Y CAGR)+131.12%
    Revenue Growth (5Y CAGR)+64.59%

    Revenue and profit by year

    Dividends and Yields

    TRAW does not pay a dividend.

    Buyback Yield-30.43%
    Shareholder Yield-30.43%

    Stock Splits

    The last split was a 1-for-25 reverse split on Sep 23, 2024.

    Last Split DateSep 23, 2024
    Split TypeReverse split
    Split Ratio1:25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TRAW

    What is TRAW's market cap?

    Traws Pharma has a market cap of $4.00M. Its enterprise value, which adds debt and subtracts cash, is $1.66M.

    How many shares of TRAW are outstanding?

    Traws Pharma has 17.04M shares outstanding. The count is up 93.28% from a year earlier.

    Does TRAW pay a dividend?

    No. Traws Pharma does not pay a dividend.

    How much debt does TRAW have?

    Traws Pharma has $0 of total debt and $2.34M of cash and equivalents, a net cash position of $2.34M.